Orthofix Medical Hits 52-Week Low at $9.47 Amid Declining Profits

Orthofix Medical, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 9.47 on May 26, 2026. This significant decline highlights the stock's ongoing struggles, as it has generated a return of -28.84% over the past year. The company's market capitalization stands at USD 477 million, reflecting its position within the microcap category. Despite the challenging performance, Orthofix maintains a debt-equity ratio of 0.22, indicating a relatively low level of debt compared to equity. However, the return on equity is notably negative at -27.08%, suggesting difficulties in generating profits from shareholders' investments. The stock's price-to-book ratio is 1.08, which may indicate that it is trading close to its book value. Additionally, the company has not paid any dividends, and its performance metrics reveal a decline in profits by 5.9% over the past year. With high institutional holdings at 100%, the stock's trading activity is closely monitored by investors with substantial resources. Overall, Orthofix Medical's recent performance underscores the challenges it faces in the current market environment.